Companies · Biotechnology

Mel-Mont Medical, Inc.

DORAL · Biotechnology

Diligence memoA one-page analyst read on Mel-Mont Medical, Inc. — recommendation, valuation, rhythm, risks.
$10.2M
Total raised · real
3
Rounds
0.0×
Latest step-up
Top 44%
Sector rank · raised
Series A
Latest stage · inferred · Thu Dec 11 2025 00:00:00 GMT+0000 (Coordinated Universal Time)

Mel-Mont Medical, Inc. looks under-valued against its niche peers and is active on financing cadence.

Synthesized from the figures below est. — every claim rests on a number shown on this page. Valuation uses the biotech sector profile.

Analyst read est. — computed against this company's niche peers in the same era. Inputs shown; not a quoted figure.

Under-valued
  • Modeled value is 0.04× the median modeled value of Series A Biotechnology companies in 2025–2027 (157 peers) — value vs value, same stage and era.
Active
  • Last raise 7 mo ago; this sector typically re-raises about every 14 months.
  • Raising on or ahead of the sector's normal rhythm.
Leadership

No named principal in this company's public records yet — see all operators below.

Explore how these operators interlock with other companies in the operator network.

Where it sits in Biotechnology

Mel-Mont Medical, Inc. is one of 4293 Biotechnology companies tracked from DORAL. By capital raised it ranks mid-pack (ahead of 57% of sector peers), and in the long tail by modeled valuation est..

Ranking is computed against this company's own sector cohort — reported capital is fact; valuation tiers are modeled.

As reported in public records reported — not modeled.

US
Jurisdiction
Rule 506(b)
Reg D exemption
3
Investors (latest)
2025-12-11
First sale
Amount raised vs valuation, by round

Solid bars are reported offering amounts reported; hatched bars are the modeled post-money valuation est. — both on one shared scale so you can read raise-vs-worth at each round directly. Use the toggles to overlay data labels and the niche-peer / market average value lines.

Amount raised · realModeled valuation · estCumulative funded · real
$0$50M$100M$150M$200MSeed · 2020-10-30 Raised $3.0M (real) Modeled valuation $111M (est)$3.0M$111MSeed2020Series A · 2023-08-25 Raised $6.9M (real) Modeled valuation $55M (est)$6.9M$55MSeries A2023Series A · 2025-12-11 Raised $250K (real) Modeled valuation $654K (est)$250K$654KSeries A2025+$6.9M+$250KCumulative $10M

The line shows cumulative reported funding over the period; + labels show new capital added between points when there is room. Toggle on-bar figures, plus the niche-peer and market averages, to read this company against its cohort. Benchmarks are modeled medians.

Financing ladder & sequence gaps
Seed$3.0M · 2020
Series A$6.9M · 2023
Series A extension$250K · 2025

Stages are modeled from round size (public records carry no series label). No record for: Pre-Seed — the company may have raised it under a different exemption, merged it into an adjacent record, or skipped it. Sequence completeness: 67%.

Modeled valuation trajectory
$654K
Base estimate est.
$273K
Conservative case
$1.0M
Upside case
$1.1M
Modeled post-money

Round size and date are reported; the stage label is inferred from round size (latest is Series Aa $4.0M–$15M round). Valuation is modeled from stage benchmarks scaled by the biotech sector profile. Directional, not a quoted figure.

Seed · modeled $111.0M · 2020-10-302020Series A · modeled $54.7M · 2023-08-25Series A · modeled $654K · 2025-12-112025
Model inputs · modeled:benchmark-stage-stepup-v1
22%
Dilution assumption
Implied ownership sold in the financing.
44%
Survival probability
24% low · 60% high
1.62×/yr
Annual markup
2.04×/yr upside case
0.6 yr
Elapsed time used
0.6 yr actual, capped for stale marks
biotech
Sector profile
Adjusts growth and survival by industry.
Financing rhythm
31 mo
Avg between rounds
$2.0M/yr
Capital velocity
5.7 yr
On record since
2020
First round
3
Rounds on file
How it compares to the market

Benchmarked against 4293 companies in Biotechnology. Each bar is a median (the middle company, not an average — outliers don't skew it). Two yardsticks: real money raised (reported on Form D) and modeled value (our estimate est.). These are whole-sector medians across all stages, except the per-stage row.

Total raised — vs sector median (real $, all stages) 1.4× above median
This company$10.2M
Sector median$7.2M
Latest round — vs other Series A rounds in sector (real $, this stage) 0.0× of median
This company$250K
Sector median$5.4M
Modeled value — vs sector median (estimate, all stages) 0.0× of median
This company$654K
Sector median$64.2M

Raised more than 57% of sector peers (real $). Modeled value above 2% of peers (estimate).

Niche peers — same stage & era

A tighter cohort than the sector chart above — only companies at the same stage (Series A) that last raised in the same ~3-year era, ranked by modeled value est. (not money raised). This is the exact set the analyst read compares against, so a like-for-like cohort is what makes "over/under-valued" meaningful. This company ranks #156 of 157.

This companyCohort peer
$100K$1.0M$10.0M$100.0M$1.0M$10.0M$100.0MCapital raised (log)Acasti Pharma Inc. · Series A Raised $23.0M · modeled $58.6M (est)Edesa Biotech, Inc. · Series A Raised $36.9M · modeled $58.5M (est)4DMedical Ltd · Series A Raised $15.0M · modeled $50.7M (est)Arialys Therapeutics, Inc. · Series A Raised $29.1M · modeled $49.2M (est)Nuclein, LLC · Series A Raised $34.5M · modeled $48.3M (est)Phantom Neuro Inc. · Series A Raised $15.4M · modeled $45.7M (est)Circulate Health, Inc. · Series A Raised $13.0M · modeled $43.3M (est)Biovantix Biotechnology, Inc · Series A Raised $15.0M · modeled $42.2M (est)Bariendo Inc. · Series A Raised $11.1M · modeled $40.9M (est)ENDRA Life Sciences Inc. · Series A Raised $26.8M · modeled $40.9M (est)Medici Therapeutics, Inc. · Series A Raised $14.8M · modeled $39.8M (est)Onconetix, Inc. · Series A Raised $22.0M · modeled $37.7M (est)Mel-Mont Medical, Inc. (this company) Raised $10.2M · modeled $654K (est)Mel-Mont Medical, Inc.
CompanyStageRaised · realValue · estvs peer med.
Acasti Pharma Inc.Series A$23.0M$58.6M3.75×
Edesa Biotech, Inc.Series A$36.9M$58.5M3.74×
4DMedical LtdSeries A$15.0M$50.7M3.24×
Arialys Therapeutics, Inc.Series A$29.1M$49.2M3.14×
Nuclein, LLCSeries A$34.5M$48.3M3.09×
Phantom Neuro Inc.Series A$15.4M$45.7M2.92×
Circulate Health, Inc.Series A$13.0M$43.3M2.77×
Biovantix Biotechnology, IncSeries A$15.0M$42.2M2.70×
Bariendo Inc.Series A$11.1M$40.9M2.61×
ENDRA Life Sciences Inc.Series A$26.8M$40.9M2.61×
Medici Therapeutics, Inc.Series A$14.8M$39.8M2.54×
Onconetix, Inc.Series A$22.0M$37.7M2.41×
Mel-Mont Medical, Inc. this companySeries A$10.2M$654K0.04×
Full financing history

Stage is inferred from round size est., not reported on the filing — a round's dollar size maps to a bucket: Pre-Seed <$1.0M · Seed $1.0M–$4.0M · Series A $4.0M–$15M · Series B $15M–$40M · Series C $40M–$100M · Series D+ $100M–$400M · Growth/Late >$400M.

StageAmount · realAnnouncedPost-money · estValue · estConf.
Seed$3.0M2020-10-30$15.0M$111.0M90%
Series A$6.9M2023-08-25$31.4M$54.7M90%
Series A$250K2025-12-11$1.1M$654K90%
What happened at each round

Step-up, pace versus the sector's normal cadence, and revenue/exemption moves — read straight from the reported round facts reported.

  1. Seed$3.0M2020-10-30
    • First recorded raise — entered as Seed.
    • 1 investor on this round.
  2. Series A$6.9M2023-08-25
    • Raised again after 34 mo — slower than the ~14 mo sector norm.
    • Round 2.3× larger than the prior — scaling up.
    • 69 investors on this round.
  3. Series A$250K2025-12-11
    • Raised again after 28 mo — slower than the ~14 mo sector norm.
    • Round 27.6× smaller than the prior — bridge or down round.
    • 3 investors on this round.
Intelligence
2028 ~Q3
Modeled next raise · ~31mo cadence
$250K
Modeled next size est.range $250K$400K
0.0×
Last step-up
$2.0M/yr
Capital velocity

Predictive signals are modeled est. from this company's own cadence and step-up, plus sector benchmarks — directional, not advice. Peer set and a CSV export live in your analyst workspace.

Key people & operators

Officers, directors and promoters named in this company's public recordsreported — the people who run it (not its investors). "Also runs" counts come from name-matching across all records, so verify before acting.

PersonRoleAlso runsTied since
Michael Torres4 other2023-08
Frank Melendez2020-10
Liliana Montes2020-10
Octavio Gonzalez Paredo2020-10
Registry & provenance

Mel-Mont Medical, Inc. is an official record sourced from the U.S. Securities and Exchange Commission (SEC). U.S. data is aggregated from SEC Form D filings.

United States
Country of record
US
Jurisdiction
1832591
SEC CIK
Similar companies

Nearest neighbours across the whole database — matched on sector, stage and capital scale, and on shared operators (officers or directors named at both companies in public filings). A discovery shortlist, not a valuation cohort — verify before acting, the same way modeled figures are directional.

CompanySectorStageRaised · realValue · estWhy similar
CrossBridge Bio, Inc.BiotechnologySeries A$10.8M$48.5Mnetwork1 shared operator · same sector · same stage
Cba Pharma IncBiotechnologySeries A$10.0M$3.6Msame sector · same stage
GelMEDIX, Inc.BiotechnologySeries A$9.9M$1.6Msame sector · same stage
Turnpoint Medical Devices, Inc.BiotechnologySeries A$9.6M$3.6Msame sector · same stage
InCellDx, Inc.BiotechnologySeries A$9.5M$2.6Msame sector · same stage
Axoft, Inc.BiotechnologySeries A$9.3M$3.1Msame sector · same stage
Biostem TechnologiesBiotechnologySeries A$9.2M$2.2Msame sector · same stage
SLAM BioTherapeutics, Inc.BiotechnologySeries A$9.2M$2.6Msame sector · same stage
Semantically similar

Matched by meaning, not labels — a local language model reads each company's name, sector and description and ranks the closest in that learned space. This catches look-alikes that cross sector boundaries; the structured list above explains its matches, this one trusts the text. Directional, like every modeled signal here.

CompanySectorStageValue · estMatch
Mellitus, LLCBiotechnologySeries A$101.3M86%
Bergen Medical Products, Inc.BiotechnologySeed$39.9M85%
Magnus Medical, Inc.BiotechnologySeries C$153.8M85%
Arsenal Medical, Inc.BiotechnologySeries A$217.6M84%
Medical Nutrition Innovation, Inc.BiotechnologySeed$55.5M84%
Panorama Medicine, Inc.BiotechnologySeed$65.8M84%
Mimio Health, IncBiotechnologySeed$24.9M84%
Mosaic Biosciences, Inc.BiotechnologySeries A$176.4M84%
Frequently asked
How much funding has Mel-Mont Medical, Inc. raised?
Mel-Mont Medical, Inc. has raised approximately $10.2M in disclosed capital across 3 recorded financing rounds, aggregated from public filings.
What is Mel-Mont Medical, Inc.'s estimated valuation?
Provath's modeled valuation for Mel-Mont Medical, Inc. is approximately $654K (modeled range $273K–$1.0M). This is an algorithmic estimate derived from round sizes and same-niche peers — not a quoted or reported figure.
What funding stage is Mel-Mont Medical, Inc. at?
Mel-Mont Medical, Inc.'s latest modeled financing stage is Series A. Its most recent recorded round closed around Thu Dec 11.
What does Mel-Mont Medical, Inc. do and where is it based?
Mel-Mont Medical, Inc. operates in the Biotechnology sector, based in DORAL.
Explore related

See where Mel-Mont Medical, Inc. sits in the wider market — its sector, location and stage cohorts, each with their own leaderboards and capital-flow timelines.

Is this your company?

If you work at Mel-Mont Medical, Inc., claim this profile or suggest a correction. We aggregate from public filings, so help us keep your description, website and links accurate.

Is this your company? Update your profile or add contact details — and choose exactly who can reach you. Reviewed before anything is published.